Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.

ABSTRACT:

Background

Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity associated with increased arterial stiffness. Plasma aldosterone levels are increased in CKD, and aldosterone has been found to increase vascular inflammation and fibrosis. It was hypothesized that aldosterone receptor inhibition with eplerenone could reduce arterial stiffness in CKD stage 3-4.

Study design

The design was randomized, open, parallel group. Measurements of arterial stiffness markers were undertaken at weeks 1 and 24.

Intervention

24 weeks of add-on treatment with 25-50 mg eplerenone or standard medication.

Outcomes

Primary outcome parameter was carotid-femoral pulse wave velocity (cfPWV). Secondary outcomes were augmentation index (AIx), ambulat

SUBMITTER: Boesby L 

PROVIDER: S-EPMC3660355 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature